Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company's strategic guidance, Hemab 1-2-5TM, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and other serious disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/21/23 | $135,000,000 | Series B |
Access Biotechnology Avoro Ventures Deep Track Capital HealthCap Invus Maj Invest Equity Novo Holdings RA Capital Management Rock Springs Capital | undisclosed |
